Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Glaukos Corp. (GKOS)
:GKOS
Holding GKOS?
Track your performance easily
GKOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$83.90 - $161.13
Previous CloseN/A
Volume137.72K
Average Volume (3M)640.81K
Market Cap
$8.63B
Enterprise Value$7.06B
Total Cash (Recent Filing)$95.76M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Feb 19, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.96
Shares Outstanding55,137,430
10 Day Avg. Volume650,226
30 Day Avg. Volume640,807
Standard Deviation0.14
R-Squared0.16
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.95
Price to Cash Flow (P/CF)-225.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue19.61
Enterprise Value/Gross Profit29.54
Enterprise Value/Ebitda-76.96
Forecast
1Y Price Target
$156.50Price Target Upside0.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Glaukos News
PremiumCompany Announcements
Glaukos Highlights Advances in Glaucoma Treatments
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGlaukos Corp reported 3Q24 revenue of $96.7M, which was well ahead of analyst and consensus estimates.
Market Adoption And GrowthThe establishment of a unique J-Code for iDose and the involvement of all sales representatives in promoting the product suggests continued growth into the next fiscal year.
Product Efficacy And Market PotentialThe company's iDose product is expected to drive significant sales growth due to its disruptive nature in interventional glaucoma treatment.
Bears Say
Financial PerformanceThe valuation is a hurdle for many investors as shares are up significantly and sit at a high EV/sales ratio.
Market DynamicsPayer dynamics can be bottlenecks to adoption, such as MAC coverage, which could impact iDose sales.
Operational ChallengesManagement noted headwinds for 4Q24, including challenges in Corneal Health due to MDRP and changes in reimbursement in Surgical Glaucoma.
---
Ownership Overview
5.91% Insiders
41.96% Mutual Funds
0.19% Other Institutional Investors
26.44% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GKOS FAQ
What was Glaukos Corp.’s price range in the past 12 months?
Glaukos Corp. lowest stock price was $83.90 and its highest was $161.13 in the past 12 months.
What is Glaukos Corp.’s market cap?
Glaukos Corp.’s market cap is $8.63B.
When is Glaukos Corp.’s upcoming earnings report date?
Glaukos Corp.’s upcoming earnings report date is Feb 19, 2025 which is in 28 days.
How were Glaukos Corp.’s earnings last quarter?
Glaukos Corp. released its earnings results on Nov 04, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.478 by $0.198.
Is Glaukos Corp. overvalued?
According to Wall Street analysts Glaukos Corp.’s price is currently Undervalued.
Does Glaukos Corp. pay dividends?
Glaukos Corp. does not currently pay dividends.
What is Glaukos Corp.’s EPS estimate?
Glaukos Corp.’s EPS estimate is -0.38.
How many shares outstanding does Glaukos Corp. have?
Glaukos Corp. has 55,137,430 shares outstanding.
What happened to Glaukos Corp.’s price movement after its last earnings report?
Glaukos Corp. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.478. Following the earnings report the stock price went down -2.679%.
Which hedge fund is a major shareholder of Glaukos Corp.?
Currently, no hedge funds are holding shares in GKOS
---
Glaukos Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$156.50 (0.07% Upside)
$156.50 (0.07% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 185.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $288.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 27.9%
Last 30 Days ▲ 27.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.99%
12-Months-Change
Fundamentals
Return on Equity
-26.10%
Trailing 12-Months
Asset Growth
-2.33%
Trailing 12-Months
Company Description
Glaukos Corp.
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
---
GKOS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with record sales and strong growth in both U.S. and international glaucoma markets, alongside promising clinical trial results for Epioxa. These achievements are somewhat tempered by challenges in corneal health revenues and ongoing reimbursement hurdles for iDose TR.Read More>---
GKOS Stock 12 Month Forecast
Average Price Target
$156.50
▲(0.07% Upside)
Technical Analysis
Integra Lifesciences
―
Inspire Medical Systems
―
Alcon
―
Bioventus
―
Masimo
―
Staar Surgical
―
Best Analysts Covering GKOS
1 Year
1 Year Success Rate
15/15 ratings generated profit
1 Year Average Return
+63.30%
assigned a buy rating 3 months ago
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +63.30% per trade.
---